Sunshine Biopharma (SBFM) Competitors $1.54 -0.06 (-3.45%) Closing price 07/11/2025 03:57 PM EasternExtended Trading$1.53 -0.01 (-0.65%) As of 07/11/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SBFM vs. ENLV, SCYX, DYAI, COEP, TPST, NRSN, CVKD, CGTX, ALXO, and CARAShould you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Enlivex Therapeutics (ENLV), SCYNEXIS (SCYX), Dyadic International (DYAI), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), Cognition Therapeutics (CGTX), ALX Oncology (ALXO), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry. Sunshine Biopharma vs. Its Competitors Enlivex Therapeutics SCYNEXIS Dyadic International Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics ALX Oncology Cara Therapeutics Sunshine Biopharma (NASDAQ:SBFM) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk. Which has preferable valuation and earnings, SBFM or ENLV? Sunshine Biopharma has higher revenue and earnings than Enlivex Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSunshine Biopharma$34.87M0.20-$5.13M-$150.88-0.01Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.94 Which has more risk and volatility, SBFM or ENLV? Sunshine Biopharma has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Does the media refer more to SBFM or ENLV? In the previous week, Sunshine Biopharma and Sunshine Biopharma both had 1 articles in the media. Enlivex Therapeutics' average media sentiment score of 1.87 beat Sunshine Biopharma's score of 0.96 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Sunshine Biopharma Positive Enlivex Therapeutics Very Positive Do analysts rate SBFM or ENLV? Sunshine Biopharma presently has a consensus price target of $15.00, indicating a potential upside of 874.03%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 681.25%. Given Sunshine Biopharma's higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is SBFM or ENLV more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -13.88%. Sunshine Biopharma's return on equity of -21.25% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sunshine Biopharma-13.88% -21.25% -16.89% Enlivex Therapeutics N/A -57.67%-50.52% Do institutionals & insiders believe in SBFM or ENLV? 42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 0.1% of Sunshine Biopharma shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummarySunshine Biopharma beats Enlivex Therapeutics on 8 of the 15 factors compared between the two stocks. Get Sunshine Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBFM vs. The Competition Export to ExcelMetricSunshine BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.02M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-0.0120.8528.2620.26Price / Sales0.20303.05437.10166.10Price / CashN/A42.1137.1257.67Price / Book0.177.638.045.49Net Income-$5.13M-$55.05M$3.19B$250.45M7 Day Performance0.33%8.43%3.62%4.79%1 Month Performance-0.65%8.14%5.98%9.59%1 Year Performance365.26%1.62%29.39%16.41% Sunshine Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBFMSunshine Biopharma3.1553 of 5 stars$1.54-3.4%$15.00+874.0%+365.3%$7.02M$34.87M-0.013ENLVEnlivex Therapeutics2.8745 of 5 stars$1.21+2.5%$10.00+726.4%-13.5%$27.91MN/A-1.8370Positive NewsSCYXSCYNEXIS0.917 of 5 stars$0.71-3.2%N/A-68.0%$27.62M$2.63M-1.2660Positive NewsDYAIDyadic International2.8768 of 5 stars$0.92-2.6%$6.00+555.4%-33.6%$27.55M$3.34M-4.587Gap DownCOEPCoeptis Therapeutics0.516 of 5 stars$7.73+2.5%N/A+57.4%$26.49M$62.87K-1.332TPSTTempest Therapeutics2.0421 of 5 stars$7.08-0.7%$30.00+323.7%-76.0%$26.26MN/A-0.3920NRSNNeuroSense Therapeutics2.5067 of 5 stars$2.09+9.4%$14.00+569.9%+105.0%$26.10MN/A-3.8710News CoverageAnalyst ForecastCVKDCadrenal Therapeutics2.7911 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404CGTXCognition Therapeutics2.9641 of 5 stars$0.58+42.9%$2.83+389.5%-71.3%$25.11MN/A-0.7820News CoverageAnalyst DowngradeGap DownHigh Trading VolumeALXOALX Oncology3.587 of 5 stars$0.44-3.5%$3.30+643.2%-93.2%$24.57MN/A-0.1840News CoverageGap UpCARACara Therapeutics0.2205 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading Volume Related Companies and Tools Related Companies ENLV Competitors SCYX Competitors DYAI Competitors COEP Competitors TPST Competitors NRSN Competitors CVKD Competitors CGTX Competitors ALXO Competitors CARA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBFM) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
